Form 4: Coherus BioSciences CEO Acquires 196,500 Shares Via Stock Option Vesting After YUSIMRY Franchise Sale

Coherus BioSciences CEO Dennis M. Lanfear acquired 196,500 shares of common stock through the vesting of a performance stock option following the closing of the YUSIMRY franchise sale.

Summary

• On July 22, 2024, Coherus BioSciences CEO Dennis M. Lanfear acquired 196,500 shares of common stock.
• This acquisition resulted from the vesting of a performance stock option granted on April 11, 2024.
• The vesting was triggered by the closing of the sale of Coherus BioSciences' YUSIMRY franchise.
• The stock option allows Lanfear to purchase shares at an exercise price of $2.41.
• Following the transaction, Lanfear directly owns 196,500 shares through the stock option.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO exercising stock options after a significant transaction (YUSIMRY sale) suggests confidence, but it's a routine event.

Positives

• The CEO's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects following the YUSIMRY franchise sale.

Industry Context

Executive compensation through stock options is a common practice in the biotechnology industry to align management's interests with those of shareholders.

Stakeholder Impact

• The vesting of stock options impacts shareholders by potentially diluting equity, but it also aligns management's interests with shareholder value.

Key Dates